TY - JOUR
T1 - Active Surveillance for Low-Risk Thyroid Cancers
T2 - A Review of Current Practice Guidelines
AU - Kim, Min Joo
AU - Moon, Jae Hoon
AU - Lee, Eun Kyung
AU - Song, Young Shin
AU - Jung, Kyong Yeun
AU - Lee, Ji Ye
AU - Kim, Ji Hoon
AU - Kim, Kyungsik
AU - Park, Sue K.
AU - Park, Young Joo
N1 - Publisher Copyright:
Copyright © 2024 Korean Endocrine Society.
PY - 2024
Y1 - 2024
N2 - The indolent nature and favorable outcomes associated with papillary thyroid microcarcinoma have prompted numerous prospective studies on active surveillance (AS) and its adoption as an alternative to immediate surgery in managing low-risk thyroid cancer. This article reviews the current status of AS, as outlined in various international practice guidelines. AS is typically recommended for tumors that measure 1 cm or less in diameter and do not exhibit aggressive subtypes on cytology, extrathyroidal extension, lymph node metastasis, or distant metastasis. To determine the most appropriate candidates for AS, factors such as tumor size, location, multiplicity, and ultrasound findings are considered, along with patient characteristics like medical condition, age, and family history. Moreover, shared decision-making, which includes patient-reported outcomes such as quality of life and cost-effectiveness, is essential. During AS, patients undergo regular ultrasound examinations to monitor for signs of disease progression, including tumor growth, extrathyroidal extension, or lymph node metastasis. In conclusion, while AS is a feasible and reliable approach for managing low-risk thyroid cancer, it requires careful patient selection, effective communication for shared decision-making, standardized follow-up protocols, and a clear definition of disease progression.
AB - The indolent nature and favorable outcomes associated with papillary thyroid microcarcinoma have prompted numerous prospective studies on active surveillance (AS) and its adoption as an alternative to immediate surgery in managing low-risk thyroid cancer. This article reviews the current status of AS, as outlined in various international practice guidelines. AS is typically recommended for tumors that measure 1 cm or less in diameter and do not exhibit aggressive subtypes on cytology, extrathyroidal extension, lymph node metastasis, or distant metastasis. To determine the most appropriate candidates for AS, factors such as tumor size, location, multiplicity, and ultrasound findings are considered, along with patient characteristics like medical condition, age, and family history. Moreover, shared decision-making, which includes patient-reported outcomes such as quality of life and cost-effectiveness, is essential. During AS, patients undergo regular ultrasound examinations to monitor for signs of disease progression, including tumor growth, extrathyroidal extension, or lymph node metastasis. In conclusion, while AS is a feasible and reliable approach for managing low-risk thyroid cancer, it requires careful patient selection, effective communication for shared decision-making, standardized follow-up protocols, and a clear definition of disease progression.
KW - Active surveillance
KW - Guideline
KW - Papillary thyroid cancer
KW - Practice guideline
KW - Thyroid neoplasms
KW - Watchful waiting
UR - http://www.scopus.com/inward/record.url?scp=85187006304&partnerID=8YFLogxK
U2 - 10.3803/EnM.2024.1937
DO - 10.3803/EnM.2024.1937
M3 - Review article
C2 - 38356210
AN - SCOPUS:85187006304
SN - 2093-596X
VL - 39
SP - 47
EP - 60
JO - Endocrinology and Metabolism
JF - Endocrinology and Metabolism
IS - 1
ER -